efinedbyavaccine-inducedantibody. Proc. Natl Acad. Sci. USA115,168–173 ticlevaccine. Biopharm. Int 23Suppl 10,26–34(201
2018). 46. Fernandes,F.etal.Insectcellsasaproductionpla
autto, G. A., Kirchenbaum, G. A. & Ross, T. M. Towards a universal influenza particles. Expert Rev. Vaccines 12,225–236(2013).
accine:differentapproachesforonegoal.Virol.J.15,17(2018). 47. Influenza vaccine strategies for broad global acces
achbagauer,R.etal.Achimerichemagglutinin-baseduniversalinfluenzavirus azureedge.net/media/documents/VAC_infl_publ_rpt_
accine approach induces broad and long-lasting immunity in a randomized, 2021.
lacebo-controlledphase Itrial. Nat. Med.27,106–114(2021). 48. European Medicines Agency. Assessment report.
renstein,W.A.&Schaffner,W.Lessonslearned:roleofinfluenzavaccinepro- EMEA/H/C/005159/0000. Available at https://www.e
uction,distribution,supply,anddemand–whatitmeansfortheprovider.Am.J. assessment-report/supemtek-epar-public-assessment-r
ed.121,S22–S27(2008). February2021.
elberbaum, R. S. The baculovirus expression vector system: a commercial 49. Health Canada. Registerof Innovative Drugs[Updat
anufacturingplatformforviralvaccinesandgenetherapyvectors.Biotechnol.J. from https://www.canada.ca/en/health-canada/serv
0,702–714(2015). drug-products/applications-submissions/register-inn
ox,M.M.&Hashimoto,Y.Afasttrackinfluenzavirusvaccineproducedininsect sed19April2021.
ells.J.Invertebr.Pathol.107,S31–S41(2011). 50. Taubenberger, J.K.Influenzavirus hemagglutinin c
aymond, D. D. etal. Influenzaimmunizationelicitsantibodiesspecificforan laughingmatter. Proc. Natl Acad. Sci. USA95,9713–
gg-adaptedvaccinestrain.Nat.Med.22,1465–1469(2016). 51. Stieneke-Gröber,A.etal.Influenzavirushemaggluti
kowronski,D.M.etal.Low2012-13influenzavaccineeffectivenessassociated siteisactivatedbyfurin,asubtilisin-likeendoprote
ith mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in (1992).PMC556715.
irculatingviruses. PLo SONE9, e 92153(2014). 52. Chen, J. etal. Structureofthehemagglutininprec
ost, S. J. etal. Contemporary H3N2influenzaviruseshaveaglycosylationsite minantofinfluenzapathogenicityandtheoriginof
hataltersbindingofantibodieselicitedbyegg-adaptedvaccinestrains.Proc. 95,409–417(1998).
atl Acad. Sci. USA114,12578–12583(2017). 53. Luczo, J. M. etal. Molecularpathogenesisof H5hig
lannery, B. et al. Interim estimates of 2016-17 seasonal influenza vaccine enza: the role of the haemagglutinin cleavage sit
ffectiveness-United States, February 2017. MMWRMorb. Mortal. Wkly Rep.66, 406–430(2015).
67–171(2017). 54. Boonstra, S. et al. Hemagglutinin-mediated mem
hu, Y.&Mc Cauley, J. GISAID: Globalinitiativeonsharingallinfluenzadata-from perspective. Annu Rev. Biophys.47,153–173(2018).
isiontoreality. Eurosurveillance: bulletin Europeensurlesmaladiestransmis- 55. Mc Craw, D. M., Gallagher, J. R.&Harris, A. K. Characte
ibles = European communicable disease bulletin 22, https://doi.org/10.2807/ hemagglutinin complexes by cryo-electron micros
560-7917.Es.2017.22.13.30494(2017). revealsstructuralpolymorphisms.Clin.Vaccin.Immu
ong,L.etal.Efficaciousrecombinantinfluenzavaccinesproducedbyhighyield 56. Kost,T.A.&Condreay,J.P.Recombinantbaculovirus
acterial expression: a solution to global pandemic and seasonal needs. PLo S insectandmammaliancells. Curr. Opin. Biotechnol.
NE3,e2257(2008). 57. Webster,R.G.,Brown,L.E.&Jackson,D.C.Change
ussey, L. et al. Phase 1 safety and immunogenicity study of a quadrivalent hemagglutininmoleculeof H3influenzavirusatacidi
easonal flu vaccine comprising recombinant hemagglutinin-flagellin fusion (1983).
roteins. Open Forum Infect. Dis.3, ofw 015(2016). 58. Lee, P. S.&Wilson, I. A. Structuralcharacterizationof
guilar-Yanez, J. M. et al. An influenza A/H1N1/2009 hemagglutinin vaccine broadly cross-reactive antibodies. Curr. Top. Microbi
roducedin Escherichiacoli. PLo SONE5, e 11694(2010). (2015).
aczynska, V. Influenzavirus hemagglutinin asavaccine antigen produced in 59. Turner, H. L. etal. Potentanti-influenza H7humanm
acteria. Acta Biochim Pol.61,561–572(2014). separation of hemagglutinin receptor-binding hea
avis, A. R. et al. Immune response to human influenza virus hemagglutinin e3000139(2019).
xpressedin Escherichiacoli. Gene 21,273–284(1983). 60. Khurana, S. etal. Repeatvaccinationreducesantibo
osales-Mendoza,S.etal.Whatdoesplant-basedvaccinetechnologyoffertothe differentinfluenzavaccineplatformsinhumans.Nat
ghtagainst COVID-19? Vaccines 8,183(2020). 61. Ekiert, D. C. et al. Antibody recognition of a highl
illet,S.etal.Aplant-derivedquadrivalentviruslikeparticleinfluenzavaccine epitope.Science324,246–251(2009).
nduces cross-reactive antibody and T cell response in healthy adults. Clin. 62. Kallewaard,N.L.etal.Structureandfunctionanalysis
mmunol.168,72–87(2016). allinfluenza Asubtypes. Cell 166,596–608(2016).
illet,S.etal.Immunogenicityandsafetyofaquadrivalentplant-derivedvirus 63. Benhaim, M. A. etal. Structural monitoring of a tr
ikeparticleinfluenzavaccinecandidate-tworandomized Phase IIclinicaltrialsin hemagglutininfusionmachineryoninfluenzavirions.
8to 49and>/=50yearsoldadults. PLo SONE14, e 0216533(2019). 64. Portnoff, A. D. etal. Influenzahemagglutininnanopa
ard, B. J. etal. Efficacy, immunogenicity, andsafetyofaplant-derived, quad- neutralizingantibodiesagainststructurallydistinctdo
ivalent, virus-like particle influenza vaccine in adults (18-64 years) and older 8,99(2020).
dults (>/=65 years): two multicentre, randomised phase 3 trials. Lancet 396, 65. Richards, K. A. etal. Recombinant HA-basedvaccine
491–1503(2020). unit vaccines in elicitation of influenza-specific C
on, S. Y. et al. Characterization of the innate stimulatory capacity of plant- dependentantibodyresponsesinhumans.NPJVacc
erived virus-like particles bearing influenza hemagglutinin. Vaccine 36, 66. Tay,T.etal.Investigationintoalternativetestingmet
028–8038(2018). tionofinfluenzavirusvaccine. Hum. Vaccines Immun
andey,A.etal.Impactofpreexistingadenovirusvectorimmunityonimmu- 67. Gallagher, J. R. et al. Characterization of hemagglu
ogenicityandprotectionconferredwithanadenovirus-based H5N1influenza virus and within vaccines using electron microsco
accine. PLo SONE7, e 33428–e 33428(2012). 10.3390/vaccines 6020031(2018).
ayedahmed, E. E. etal. Adenoviral vector-based vaccine platforms for devel- 68. Public Health Agencyof Canada. Oculo-respiratorysy
pingthenextgenerationofinfluenzavaccines.Vaccines8,574(2020). vaccination:reviewofpost-marketing surveillance t
iang, K. et al. Progress on adenovirus-vectored universal influenza vaccines. sonsin Canada. Can. Commun. Dis. Rep.31,217–22
um. Vaccin Immunother.11,1209–1222(2015). 69. Choudhri, Y.&Walop, W. Influenzavaccine-associate
hen,J.R.etal.Betterinfluenzavaccines:anindustryperspective.J.Biomed.Sci. passive surveillance, Canada 2001-2002. Can. Com
7,33(2020). (2002).
eport to the president on reengeneering the influenza vaccine production 70. Babiuk, S. etal. Aggregatecontentinfluencesthe T
nterprisetomeetthechallengesofpandemicinfluenza.Availableathttps:// influenzavaccine:evidencefromamousemodel.J.M
bamawhitehouse.archives.gov/sites/default/files/microsites/ostp/PCAST- 71. Wei,C.J.etal.Cross-neutralizationof1918and20
nfluenza-Vaccinology-Report. pdf. Accessed August 2021. glycansinviralevolutionandvaccinedesign. Sci. Tr
ópez-Macías,C.etal.Safetyandimmunogenicityofavirus-likeparticlepan- 72. An, Y. et al. N-glycosylation of seasonal influenz
emic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo- implicationforpotencytestingandimmuneproces
ontrolledtrialofadultsin Mexico. Vaccine 29,7826–7834(2011). 10.1128/JVI.01693-18(2019).